Edwards Lifesciences stock wavered Wednesday, though the heart-valve replacement maker issued a bullish outlook for 2026.

The heart valve specialist reported a second straight quarter of double-digit TAVR sales growth and credited recent study ...

Edwards Lifesciences reports strong Q4 2025 results with 13.3% sales growth to $1.57B, driven by TAVR and TMTT performance ...

Several medical societies supported extending Medicare coverage for TAVR to patients with asymptomatic aortic stenosis, but some physicians and rival Medtronic said more data is needed.

Investors reacted positively to Edwards’ 2026 guidance with shares up 1.25% in after-hours trading following the announcement.

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Medtronic has agreed to buy up to $90 million worth of ...

A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...